A Study of Tirzepatide (LY3298176) in Chinese Participants Without Type 2 Diabetes Who Have Obesity or Overweight (SURMOUNT-CN)

Sponsor
Eli Lilly and Company
Study ID
NCT05024032
Phase
PHASE3
Status
Completed

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Tirzepatide — DRUG
    Administered SC
  • Placebo — DRUG
    Administered SC

Study Details

This is a study of tirzepatide in Chinese participants without Type 2 Diabetes who have obesity or overweight. The main purpose is to learn more about how tirzepatide affects body weight.

Key Dates

Start date
Sep 1, 2021
Status verified
Dec 2023
Primary completion
Dec 27, 2022
Completion
Dec 27, 2022

Study Design

Enrollment
210 participants (actual)
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT

Arms

  • Experimental: 10 Milligrams (mg) Tirzepatide
    Participants received maintenance dose 10 mg with dose escalation starting from 2.5 mg, 5 mg, 7.5 mg, and then 10 mg tirzepatide administered subcutaneously (SC) once weekly (QW).
  • Experimental: 15 mg Tirzepatide
    Participants received maintenance dose 15 mg with dose escalation starting from 2.5 mg, 5 mg, 7.5 mg, 10 mg, 12.5 mg and then 15 mg tirzepatide administered SC QW.
  • Placebo Comparator: Placebo
    Participants received matching placebo SC QW.

Primary Outcome Measure

Mean Percent Change From Baseline in Body Weight [ Time Frame: Baseline, Week 52 ]

Related Studies